Cargando…

Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial

AIMS: Effective and safe decongestion remains a major goal for optimal management of patients with acute heart failure (AHF). The effects of the sodium–glucose cotransporter 2 inhibitor empagliflozin on decongestion-related endpoints in the EMPULSE trial (NCT0415775) were evaluated. METHODS AND RESU...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biegus, Jan, Voors, Adriaan A, Collins, Sean P, Kosiborod, Mikhail N, Teerlink, John R, Angermann, Christiane E, Tromp, Jasper, Ferreira, Joao Pedro, Nassif, Michael E, Psotka, Mitchell A, Brueckmann, Martina, Salsali, Afshin, Blatchford, Jonathan P, Ponikowski, Piotr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805406/ https://www.ncbi.nlm.nih.gov/pubmed/36254693 http://dx.doi.org/10.1093/eurheartj/ehac530

Ejemplares similares

Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial
por: Voors, Adriaan A., et al.
Publicado: (2022)

Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial
por: Kosiborod, Mikhail N., et al.
Publicado: (2022)

Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial
por: Tromp, Jasper, et al.
Publicado: (2021)

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
por: Voors, Adriaan A., et al.
Publicado: (2022)

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure
por: Abraham, William T., et al.
Publicado: (2019)

Timing of decongestion and its impact on acute heart failure prognosis
por: Kosiorek, Aneta, et al.
Publicado: (2023)

Effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure
por: Beusekamp, Joost C., et al.
Publicado: (2021)

Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial( )
por: Doehner, Wolfram, et al.
Publicado: (2022)

Hepatorenal dysfunction identifies high‐risk patients with acute heart failure: insights from the RELAX‐AHF trial
por: Biegus, Jan, et al.
Publicado: (2019)

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
por: Fitchett, David, et al.
Publicado: (2021)

Targeting the Lymphatic System for Interstitial Decongestion
por: Martens, Pieter, et al.
Publicado: (2021)

Optimal quantum network decongestion strategies
por: Perju Verzotti, Luca, et al.
Publicado: (2023)

Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials
por: Lund, Søren S., et al.
Publicado: (2021)

Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced
por: Ferreira, João Pedro, et al.
Publicado: (2022)

The effect of decongestion on nasal airway patency and airflow
por: Xiao, Qiwei, et al.
Publicado: (2021)

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2016)

Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2022)

Decongestion: Diuretics and other therapies for hospitalized heart failure
por: Vazir, Ali, et al.
Publicado: (2016)

How to interpret serum creatinine increases during decongestion
por: Chávez-Íñiguez, Jonathan S., et al.
Publicado: (2023)

Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study
por: Nishimura, Rimei, et al.
Publicado: (2015)

Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
por: Butler, Javed, et al.
Publicado: (2022)

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
por: Packer, Milton, et al.
Publicado: (2020)

Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
por: Boorsma, Eva M., et al.
Publicado: (2020)

Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials
por: Salsali, A., et al.
Publicado: (2016)

Contemporary decongestant practices of Canadian otolaryngologists for endoscopic sinus surgery
por: Reid, Jonathan W., et al.
Publicado: (2019)

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
por: Butler, Javed, et al.
Publicado: (2021)

Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study
por: Metra, Marco, et al.
Publicado: (2010)

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial
por: Roden, Michael, et al.
Publicado: (2015)

New frontiers for management of hyperkalaemia: the emergence of novel agents
por: Nassif, Michael E, et al.
Publicado: (2019)

Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure
por: Ceelen, Daan, et al.
Publicado: (2022)

Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction
por: van Essen, Bart J., et al.
Publicado: (2022)

Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
por: Butler, Javed, et al.
Publicado: (2021)

Getting ahead of the game: in-hospital initiation of HFrEF therapies
por: Biegus, Jan, et al.
Publicado: (2022)

Pathophysiology and Treatment Opportunities of Iron Deficiency in Heart Failure: Is There a Need for Further Trials?
por: Tkaczyszyn, Michał, et al.
Publicado: (2023)

Nasal decongestant and chronic headache: a case of naphazoline overuse headache?
por: Di Lorenzo, Cherubino, et al.
Publicado: (2013)

Loop diuretics in acute heart failure: beyond the decongestive relief for the kidney
por: Palazzuoli, Alberto, et al.
Publicado: (2015)

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial
por: Anker, Stefan D., et al.
Publicado: (2020)

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
por: Pellicori, Pierpaolo, et al.
Publicado: (2020)

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
por: Butler, Javed, et al.
Publicado: (2021)

Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial
por: Packer, Milton, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c11m4ebef4anlg0c3uoh8vk337